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Abstract
Background: It has been reported that higher levels of oxidative stress and inflammation play a key role in the
progression of hepatocellular carcinoma (HCC) after surgery. Coenzyme Q10 is an endogenous lipid-soluble antioxidant.
To date, no intervention study has investigated coenzyme Q10 supplementation in HCC patients after surgery.
The purpose of this study was to investigate oxidative stress, antioxidant enzymes activity, and inflammation
levels in HCC patients after surgery following administration of coenzyme Q10 (300 mg/day).
Methods: This study was designed as a single-blinded, randomized, parallel, placebo-controlled study. Patients
who were diagnosed with primary HCC (n = 41) and were randomly assign to a placebo (n = 20) or coenzyme
Q10 (300 mg/day, n = 21) group after surgery. The intervention lasted for 12 weeks. Plasma coenzyme Q10, vitamin E,
oxidative stress antioxidant enzymes activity and inflammatory markers levels were measured.
Results: The oxidative stress (p = 0.04) and inflammatory markers (hs-CRP and IL-6, p < 0.01) levels were significantly
decreased, and the antioxidant enzymes activity was significantly increased (p < 0.01) after 12 weeks of coenzyme Q10
supplementation. In addition, the coenzyme Q10 level was significantly negatively correlated with the oxidative stress
(p = 0.01), and positively correlated with antioxidant enzymes activity (SOD, p = 0.01; CAT, p < 0.05; GPx, p = 0.04) and
vitamin E level (p = 0.01) after supplementation.
Conclusion: In conclusion, we demonstrated that a dose of 300 mg/d of coenzyme Q10 supplementation
significantly increased the antioxidant capacity and reduced the oxidative stress and inflammation levels in HCC
patients after surgery.
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Background
The most recent World Health Organization (WHO,
2014) report indicated that liver cancer is the second
leading cause of cancer deaths worldwide, and 0.8 mil-
lion people (9.1 % of the global population) died from
liver cancer [1]. In Taiwan, liver cancer is also the sec-
ond leading cause of cancer deaths among men and
women (Ministry of Health and Welfare, 2014). Hepa-
tocellular carcinoma (HCC) accounts for most liver
cancers [2]. The major risk factors for HCC include
hepatitis B or C virus, alcoholic liver disease, and most
likely, nonalcoholic fatty liver disease [2]. Recently, it
has been reported that higher level of oxidative stress
and inflammation play a key role in the progression of
HCC [3]. Oxidative stress may increase via the gener-
ation of reactive oxygen species (ROS) and defects in
redox defense mechanisms with antioxidant enzymes,
such as superoxide dismutase (SOD), catalase (CAT),
or glutathione peroxidase (GPx), in mitochondria [4].
This mitochondrial dysfunction may lead to pathological
mechanisms of chronic hepatic inflammation and subse-
quent hepatocarcinogenesis [3]. A case-control study has
recently found that patients with HCC had significantly
higher levels of oxidative stress, inflammation, and lower
antioxidant capacities [5]. Consequently, it is worth trying
an agent that can lower oxidative stress and reduce in-
flammation in patients with HCC.
Coenzyme Q10 (also called ubiquinone) is a lipid-
soluble benzoquinone that has 10 isoprenyl units in its
side chain and is a key component of the mitochondrial
respiratory chain for adenosine triphosphate synthesis
[6, 7]. Additionally, coenzyme Q10 is an intracellular
antioxidant that protects membrane phospholipids,
mitochondrial membrane protein, and LDL-C from free
radical-induced oxidative damage [8, 9]. In vivo studies
have demonstrated that coenzyme Q10 has therapeutic
and chemotherapeutic effects by modulating the expres-
sion of hepPar-1, alpha-fetoprotein, inducible nitric
oxide synthase, cyclooxygenase-2 and nuclear factor-κB
(NF-κB) in the liver tissue of rats with HCC [10, 11].
However, to date, no published study has investigated
the anti-oxidative and anti-inflammation effects of coen-
zyme Q10 supplementation in patients with HCC. Thus,
the purpose of this clinical study was to examine the
levels of oxidative stress, antioxidant enzymes activity,
and inflammation after coenzyme Q10 supplementation
(300 mg/day) in patients with HCC.
Methods
Participants
This study was designed as a single-blinded, randomized,
parallel, placebo-controlled study. Following tumor re-
section, patients who were diagnosed with primary HCC
(International Classification of Diseases 9, code 155.0)
were recruited from the Division of General Surgery of
Taichung Veterans General Hospital. We excluded
patients who were younger than 20 years of age or
older than 80 years of age, as well as during pregnant
or lactating women, patient undergoing chemotherapy
or hormone therapy, those with a history or current
diagnosis of cardiovascular or renal disease, and those
taking warfarin or statin medications. For patients tak-
ing vitamins supplements, we asked them to stop tak-
ing the supplements for at least for 1 month before
enrolling in the study. Informed consent was obtained
from each subject. This study was approved by the
Institutional Review Board of Taichung Veterans General
Hospital, Taiwan and registered at Clinical Trials.gov
(NCT01964001).
Using a sample size calculation, we expected that the
change in the levels of malondialdehyde would be 0.15
± 0.2 μM after the coenzyme Q10 supplementation;
therefore, the desired power was set at 0.8 to detect a
true effect and at an α value equal to 0.05, with a mini-
mum of 16 subjects in each intervention group. We
enrolled 41 HCC patients in this study, and we used a
random numbers table to randomly assign the subjects
to the placebo (n = 20) or coenzyme Q10 (Q10-300
group, n = 21) group. The coenzyme Q10 and placebo
(starch) capsules were commercially available prepara-
tions (New Health Co., Ltd. Taichung, Taiwan). The
intervention was administered for 12 weeks. The subjects
were instructed to take two capsules daily (coenzyme Q10
supplements 300 mg/d, 150 mg/b.i.d). To monitor compli-
ance, we determined the degree of compliance for each
patient, according to the number of returning capsules,
and we measured the coenzyme Q10 level every 4 weeks
after the supplementation. The following data were re-
corded for all subjects: age, blood pressures, and smoking
and drinking habits, and exercise frequency. Body weight,
height, waist and hip circumferences were measured; and
the body mass index (BMI) and the ratio of waist to hip
were calculated.
Blood collection and biochemical measurements
Fasting venous blood samples (15 mL) were obtained to
estimate each patient’s hematological and vitamin status.
Blood specimens were collected in Vacutainer tubes
(Becton Dickinson, Rutherford, NJ, USA) that contained
EDTA as an anticoagulant or that contained no anti-
coagulant as required. Serum and plasma were prepared
after centrifugation (3000 rpm, 4 °C, 15 min) and were
then stored at -80 °C until analysis. Hematological en-
tities, such as blood urea nitrogen, creatinine, glutamic
oxaloacetic transaminase, glutamic pyruvate transamin-
ase (GPT), and lipid profiles were measured using an
automated biochemical analyzer (Hitachi-7180E, Tokyo,
Japan). The level of high sensitivity C-reactive protein
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(hs-CRP) was quantified by particle-enhanced immuno-
nephelometry with an image analyzer (Dade Behring,
IL, USA). Plasma tumor necrosis factor-α (TNF-α)
(R&D Systems Inc., Minneapolis, USA) and interleukin-
6 (IL-6) (eBioscience, CA, USA) levels were measured
using an enzyme-linked immunosorbent assay (ELISA)
with commercially available kits, according to the man-
ufacturer’s instructions.
Plasma coenzyme Q10 and vitamin E levels were
measured using high-performance liquid chromatog-
raphy (HPLC) and were detected with a UV detector at
275 nm and 292 nm, respectively [12, 13]. Plasma mal-
ondialdehyde (MDA) was determined using the TBARs
(thiobarbituric acid reactive substances) method, as
described by Botsoglou [14]. The red blood cell (RBC)
samples were washed with normal saline after remov-
ing the plasma. Then, the RBC samples were diluted
with 25x sodium phosphate buffer for superoxide
dismutase (SOD) and glutathione peroxidase (GPx)
measurements, with 250x sodium phosphate buffer for
the catalase (CAT) measurement. The antioxidant en-
zymes activities (CAT, SOD, and GPx) were determined
in the fresh samples and the methods used to measure
these activities have been previously described [15–17].
The protein content of the plasma and RBC was deter-
mined based on the biuret reaction of the bicinchoninic
acid (BCA) kit (Thermo, Rockford, IL, USA). The values of
the antioxidant enzymes activities were expressed as unit/
mg of protein. All analyses were performed in duplicate.
Fig. 1 Flow Diagram
Table 1 Characteristics of subjects
Placebo (n = 19) Q10-300 (n = 20)
males (n, %) 12 (63.2 %) 15 (75.0 %)
age (y) 61.5 ± 11.0 (62.0)a 59.7 ± 8.3 (58.5)
SBP (mmHg) 133.8 ± 18.0 (134.0) 124.8 ± 19.3 (119.5)
DBP (mmHg) 77.9 ± 11.2 (78.0) 76.9 ± 12.3 (76.0)
waist circumference
(cm)
89.1 ± 7.8 (88.0) 86.7 ± 10.2 (88.5)
waist hip ratio 0.92 ± 0.05 (0.91) 0.94 ± 0.16 (0.94)
BMI (kg/m2) 24.7 ± 3.2 (24.5) 23.1 ± 2.6 (22.8)
current smokerb, n (%) 6 (31.6 %) 5 (25.0 %)
drinks alcoholc, n (%) 3 (15.8 %) 3 (15.0 %)
Exercised, n (%) 9 (47.4 %) 8 (40.0 %)
Hepatitis B, n (%) 14 (73.7 %) 12 (60.0 %)
Hepatitis C, n (%) 4 (21.1 %) 7 (35.0 %)
Cirrhosis, n (%) 6 (31.6 %) 5 (25.0 %)
Recurrence, n (%) 3 (15.8 %) 4 (20.0 %)
Hematology
BUN (mg/dL) 15.5 ± 4.9 (15.0) 17.1 ± 9.2 (15.5)
creatinine (mg/dL) 0.8 ± 0.3 (0.8) 0.9 ± 0.3 (0.9)
GOT (IU/L) 35.2 ± 24.8 (27.0) 40.4 ± 23.0 (31.5)
GPT (IU/L) 44.8 ± 36.6 (38.0) 55.5 ± 39.8 (45.5)
TC (mg/dL) 162.7 ± 36.4 (148.0) 162.1 ± 32.7 (156.0)
TG (mg/dL) 95.3 ± 42.3 (87.0) 93.4 ± 29.9 (92.5)
LDL-C (mg/dL) 100.4 ± 32.3 (90.0) 102.3 ± 32.8 (100.0)
HDL-C (mg/dL) 50.6 ± 11.6 (50.0) 49.2 ± 12.4 (47.5)
TC / HDL-C 3.3 ± 1.0 (2.9) 3.5 ± 1.0 (3.5)
Dietary intake
Energy (kcal/d) 1608.5 ± 334.5 (1531.2) 1686.5 ± 460.8 (1655.8)
Protein (g/d) 65.9 ± 17.9 (68.0) 66.2 ± 21.2 (66.8)
% of total calories 16.6 % 15.7 %
Fat (g/d) 49.5 ± 23.9 (48.2) 50.6 ± 16.1 (51.7)
% of total calories 26.6 % 26.8 %
carbohydrate (g/d) 228.6 ± 40.8 (227.0) 251.1 ± 89.6 (238.6)
% of total calories 57.2 % 57.9 %
PUFA (g/d) 15.6 ± 11.8 (13.0) 13.8 ± 8.6 (11.1)
MUFA (g/d) 15.1 ± 9.5 (11.9) 15.3 ± 6.6 (15.6)
SFA (g/d) 12.8 ± 8.0 (10.3) 14.2 ± 5.7 (14.3)




vitamin E (mg α-T.E./d) 421.6 ± 727.1 (21.5) 615.0 ± 989.3 (10.8)
cholesterol (mg/d) 250.0 ± 163.8 (238.2) 231.8 ± 117.6 (197.8)
dietary fiber (g/d) 13.0 ± 6.5 (11.9) 10.9 ± 6.1 (9.7)
BMI body mass index, BUN blood urea nitrogen, GOT glutamic oxaloacetic
transaminase, HCC hepatocellular carcinoma, HDL-C high-density
lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, MUFA
monounsaturated fatty acid, PUFA polyunsaturated fatty fat, SFA saturated
fatty acid, TC total cholesterol, TG triglyceride
ameans ± SD (medians)
bcurrent smoker: individuals currently smoking one or more cigarettes per day
cdrinks alcohol: individuals drinking one or 1 more alcoholic drinks per day regularly
dexercise: individuals who exercise regularly at least 3 times every week
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Statistical analyses
The data were analyzed using SigmaPlot software (ver-
sion 12.0, Systat, San Jose, CA, USA). The normality of
the distribution of the variables was evaluated using the
Shapiro-Wilk test. When comparing the continuous
variables between the placebo and the Q10-300 groups,
Student’s t-test or the Mann-Whitney rank sum test
was used. For categorical response variables, the differ-
ences between the two groups were assessed using the
Chi-square test or Fisher’s exact test. When comparing
the levels of coenzyme Q10, vitamin E, and antioxidant
enzymes activities at week 0, 4, 8, and week 12 within
the group, one-way repeated measures ANOVA or
Friedman repeated measures ANOVA on ranks was
performed, and used Holm-Sidak post hoc test to assess
the statistically significant differences. When comparing
the levels of inflammatory markers at week 0 and week
12 within the group, paired-t test was performed. To
examine the correlation between the coenzyme Q10
level and the levels of vitamin E, antioxidant enzymes
activities, and inflammatory markers after the supple-
mentation, Spearman rank order correlation was used.
Additionally, simple linear regressions were used to
examine the correlations between the changes in the
levels of coenzyme Q10 and the changes in the levels of
oxidative stress, antioxidant enzymes activity, and vita-
min E. The results were considered to be statistically
significant at P < 0.05. The values presented in the text
are the means ± standard deviation (medians).
Results
Characteristics and dietary intake of subjects
The sampling and trial profiles are summarized in Fig. 1,
along with the number of subjects who completed the
study in each group. Thirty-nine subjects completed the
intervention (placebo, n = 19; Q10-300, n = 20). Table 1
shows the demographic characteristics and the dietary
intakes of the subjects. At baseline, there were no signifi-
cant between group differences in terms of age, blood
pressure, anthropometric measurements, hematological
entities, and dietary intake, as well as the frequency of
smoking, drinking, or exercise. A total of 66.7 % of the
subjects had hepatitis B, and 28.2 % of the subjects had
hepatitis B or cirrhosis. In addition, 82.0 % of the sub-
jects were newly diagnosed with HCC.
Levels of coenzyme Q10, antioxidant capacity,
and inflammation after supplementation
The levels of coenzyme Q10, vitamin E, oxidative
stress, and antioxidant enzymes after intervention are
shown in Table 2 and Fig. 2. The plasma coenzyme
Q10 concentration was significantly increased after
the coenzyme Q10 supplementation (P < 0.01). Sub-
jects in the Q10-300 group had significantly higher
levels of coenzyme Q10 than those in the placebo
group at weeks 4, 8, and 12 (P < 0.01). The plasma
MDA level was significantly decreased after the coen-
zyme Q10 supplementation (1.48 ± 0.58 μM decreased
to 1.22 ± 0.31 μM, P = 0.04) and in the patients in the
Table 2 Changes in the levels of coenzyme Q10, vitamin E, oxidative stress, antioxidant enzymes activities, and inflammation in HCC
patients after supplementation
Placebo (n = 19) Q10-300 (n = 20)
Week 0 Week 12 Week 12-0b Week 0 Week 12 Week 12-0
coenzyme Q10 (μM) 0.32 ± 0.14 (0.33)a 0.38 ± 0.09 (0.37) 0.11 ± 0.15 (0.09) 0.27 ± 0.08 (0.27) 1.47 ± 0.82 (1.58)e,d 1.19 ± 0.84 (1.35)d
vitamin E (μM) 11.84 ± 2.98 (11.66) 12.04 ± 4.13 (11.47) 0.20 ± 2.79 (0.51) 11.16 ± 2.20 (12.10) 11.52 ± 3.28 (10.54) 0.43 ± 2.29 (0.54)
Oxidative stress
MDA (μM) 1.37 ± 0.34 (1.42) 1.41 ± 0.30 (1.37) 0.08 ± 0.35 (0.11) 1.48 ± 0.58 (1.33) 1.22 ± 0.31 (1.10)e,d −0.27 ± 0.68 (−0.33)d
Antioxidant enzymes activity
SOD (U/mg protein) 16.94 ± 8.78 (13.10) 17.12 ± 5.79 (16.90) 0.73 ± 11.37 (3.00) 13.93 ± 4.35 (13.16) 21.26 ± 7.86 (22.02)e,d 7.96 ± 7.15 (7.50)d
CAT (U/mg protein) 16.36 ± 7.97 (12.00) 15.24 ± 6.62 (12.80) −1.71 ± 6.25 (0.29) 14.74 ± 7.63 (11.75) 18.00 ± 6.82 (16.76)e,d 3.28 ± 7.76 (4.80)d
GPx (U/mg protein) 15.22 ± 5.76 (14.66) 12.73 ± 5.46 (12.20) −1.10 ± 7.26 (−0.60) 15.94 ± 4.77 (17.46) 19.40 ± 8.34 (22.08)e,d 4.08 ± 7.67 (4.70)d
Inflammatory markers
hs-CRP (mg/L) 3.5 ± 3.6 (1.6) 2.1 ± 3.9 (0.8) −1.5 ± 4.2 (−0.8) 4.2 ± 4.2 (2.8) 2.6 ± 4.2 (1.0)e −1.7 ± 4.8 (−1.3)
TNF-α (pg/mL) 0.89 ± 0.71 (1.16) 1.77 ± 4.38 (0.73) 0.88 ± 4.59 (−0.10) 0.84 ± 0.78 (0.73) 1.06 ± 1.02 (0.86) 0.30 ± 1.19 (0.02)
IL-6 (pg/mL) 3.76 ± 2.30 (3.44) 2.83 ± 3.64 (1.34) −1.05 ± 3.72 (−1.65) 3.07 ± 2.03 (1.98) 1.62 ± 0.75 (1.70)e −0.49 ± 2.96 (−0.70)
CAT Catalase activity, GPx glutathione peroxidase, HCC hepatocellular carcinoma, hs-CRP high sensitivity C-reactive protein, IL-6 interleukin-6, MDA Malondialdehyde,
SOD superoxide dismutase, TNF-α tumor necrosis factor-α
ameans ± SD (medians)
bDifference between week 12 and week 0
dvalues are significantly different between the two groups
evalues are significantly different within each group
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placebo group at week 12 (1.22 ± 0.31 μM vs. 1.41 ±
0.30 μM, P = 0.04). In terms of the antioxidant enzymes
activity, the SOD (13.93 ± 4.35 U/mg protein increased
to 19.39 ± 4.79 U/mg protein, P < 0.01) and GPx activities
(15.94 ± 4.77 U/mg protein increased to 18.82 ± 7.03 U/
mg protein, P < 0.01) were significantly increased after
8 weeks of coenzyme Q10 supplementation and the CAT
activity was significantly increased after 4 weeks of
coenzyme Q10 supplementation (14.74 ± 7.63 U/mg
protein increased to 18.32 ± 12.03 U/mg protein, P
< 0.01).
The post-supplementation changes in the levels of co-
enzyme Q10, vitamin E, oxidative stress, antioxidant
enzymes activities, and inflammation in HCC patients
are also shown in Table 2. After 12 weeks of supple-
mentation, subjects in the Q10-300 supplementation
showed an increased level of changes in their level of
coenzyme Q10 (P < 0.01) and antioxidant enzymes ac-
tivity (SOD, P = 0.03; CAT, P = 0.01; GPx, P < 0.01) than
those in the placebo group. The levels of MDA (P < 0.01)
and inflammatory markers were significantly lower in the
Q10-300 group compared to the placebo group after
12 weeks of supplementation (hs-CRP, 4.2 ± 4.2 mg/L
decreased to 2.6 ± 4.2 mg/L, P < 0.01; IL-6, 3.07 ± 2.03 pg/
mL decreased to 1.62 ± 0.75 pg/mL, P < 0.01). However,
the levels of vitamin E (P = 0.81) and inflammatory
markers (hs-CRP, P = 0.64, TNF-α, P = 0.68, IL-6, P =
0.80), as well as the difference between week 12 and
week 0 of inflammatory markers (hs-CRP, P = 0.58,
TNF-α, P = 0.29, IL-6, P = 0.13) were not significantly dif-
ferent between the placebo and Q10-300 groups after
supplementation.
Fig. 2 Levels of coenzyme Q10, vitamin E, oxidative stress, and antioxidant enzymes after supplementation. †values are significantly different
between the two groups. *values are significantly different within each group. CAT, catalase activity; GPx, glutathione peroxidase; HCC,
hepatocellular carcinoma; MDA, malondialdehyde; SOD, superoxide dismutase
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Correlations between coenzyme Q10, antioxidant
capacity, and inflammation after supplementation
The correlations between coenzyme Q10, vitamin E,
oxidative stress, antioxidant enzymes activities, and in-
flammation after supplementation are shown in Table 3.
The plasma coenzyme Q10 concentration was signifi-
cantly correlated with the levels of vitamin E (r = 0.30,
P = 0.01), MDA (r = -0.43, P = 0.01), and antioxidant en-
zymes activities (SOD, r = 0.31, P = 0.01; CAT, r = 0.24,
P < 0.05; GPx, r = 0.25, P = 0.04) after 12 weeks of sup-
plementation. However, there was no significant associ-
ation between the levels of coenzyme Q10 and
inflammatory markers after supplementation.
Furthermore, we examined the correlations between
the changes in the levels of coenzyme Q10 and oxidative
stress, antioxidant enzymes, and vitamin E (Fig. 3).
Changes in the levels of coenzyme Q10 was signifi-
cantly correlated with changes in the levels of MDA
(β = -0.29, p = 0.02), antioxidant enzymes activity
(SOD, β = 2.57, p = 0.02; CAT, β = 4.47, p < 0.01; β =
3.53, p = 0.03), and vitamin E (β = 1.44, p = 0.01).
Discussion
This is the first clinical study to demonstrate that coen-
zyme Q10 (at a dose of 300 mg/d for 12 weeks) in-
creases antioxidant enzymes activities (SOD, CAT, and
GPx) and decreases oxidative stress and inflammation
in patients with HCC. Coenzyme Q10 shows a signifi-
cant anticarcinogenic activity in various cancer models
via its antioxidant and anti-inflammatory properties
[10, 11,18, 19]. Coenzyme Q10 is a highly safe and well
tolerable supplement. Because coenzyme Q10 is a well
antioxidant and anti-inflammation agent, it may repre-
sent a potential complementary therapeutic option in
chronic disease patients who suffer from a higher status
of oxidative stress or inflammation [20–22].
In this study, subjects in both groups had a low level
of coenzyme Q10 (normal ranges: 0.5–1.7 μM) [23] at
baseline (0.30 ± 0.11 μM). After a 4-week supplementa-
tion of coenzyme Q10 supplementation at a dose of
300 mg/d, the low level of coenzyme Q10 rapidly and
significantly increased in patients with HCC (0.27 ±
0.08 μM to 1.31 ± 0.63 μM, p < 0.01), and this level was
sustained for 12 weeks. Additionally, antioxidant enzyme
activity significantly increased after the coenzyme Q10
supplementation, the CAT activity was significantly in-
creased by 25.5 % after 4 weeks of supplementation, and
SOD, CAT, and GPx were significantly increased by
43.2 %, 40.4 %, and 13.4 % after 8 weeks of supplementa-
tion. After 12 weeks of coenzyme Q10 supplementation,
SOD, CAT, and GPx were significantly increased by
67.3 %, 42.6 %, and 26.5 % and oxidative stress (MDA)
was significantly decreased by 17.3 %. Although there
was no significant difference in the level of vitamin E
after 12 weeks of supplementation, there was a signifi-
cantly positive correlation between the levels of coen-
zyme Q10 and vitamin E after supplementation. Because
patients with HCC suffer from a higher level of oxidative
stress and inflammation [5], and a deficiency in coen-
zyme Q10 was found in HCC patients, we suggest that
the administration of coenzyme Q10 supplements in pa-
tients with HCC during the surgery may be beneficial.
Administered coenzyme Q10 at dose of 300 mg/d to
HCC patients can significantly increase their antioxidant
capacity, protect vitamin E against superoxide-driven
oxidation and regenerate/maintain the level of vitamin E
during antioxidation processes [24, 25].
Patients infected with hepatitis B and hepatitis C
viruses account for 65–80 % of HCC worldwide [26]. In
the present study, 66.7 and 28.2 % of the patients with
HCC had a history of infection with hepatitis B and
hepatitis C viruses, respectively. These chronic infections
cause liver inflammation, and may lead to liver fibrosis/
cirrhosis or HCC [27]. In this study, a total of 69.2 % of
the subjects (N = 27, placebo, n = 11; Q10-300, n = 16)
had chronic inflammation (hs-CRP ≥ 1.0 mg/L) and
38.5 % of the subjects (N = 15, placebo, n = 5; Q10-300,
n = 10) had a higher level of inflammation (hs-CRP ≥
3.0 mg/L) after surgery. After 12 weeks of coenzyme
Q10 supplementation, the levels of hs-CRP and IL-6
were significantly decreased (Table 2), although the
levels of inflammatory markers were not significantly
lower compared to the placebo group and no significant
association between the level of coenzyme Q10 and in-
flammatory markers after intervention (Table 3). We
failure to detect significant correlations between the
Table 3 Correlations between coenzyme Q10 level and vitamin E,
oxidative stress, antioxidant enzymes activity and inflammation in
HCC patients after supplementation
Coenzyme Q10 level (μM)
ra (p values)
vitamin E (μM) 0.30 (0.01)
Oxidative stress
MDA (μM) −0.43 (0.01)
Antioxidant enzymes activity
SOD (U/mg protein) 0.31 (0.01)
CAT (U/mg protein) 0.24 (< 0.05)
GPx (U/mg protein) 0.25 (0.04)
Inflammatory markers
hs-CRP (mg/L) 0.12 (0.49)
TNF-α (pg/mL) 0.01 (0.96)
IL-6 (pg/mL) 0.00 (0.99)
CAT Catalase activity, MDA Malondialdehyde, GPx glutathione peroxidase, HCC
hepatocellular carcinoma, hs-CRP high sensitivity C-reactive protein, IL-6
interleukin-6, SOD superoxide dismutase, TNF-α tumor necrosis factor-α
acorrelation coefficient
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levels of coenzyme Q10 and inflammatory markers
maybe due to higher variations of inflammation status
in patients with HCC after surgery. Surgical resection
is the most efficient treatment of patients with HCC.
However, surgery may elicits the activation of the
systemic inflammatory, endocrine/metabolic, and im-
munological systems, which is referred to as the surgi-
cal stress response [28]. However, Coenzyme Q10, as
an antioxidant, could inhibit the inflammatory cascade
of NF-κB -activation by the ROS [29–31]. Therefore, it
may be useful to decrease inflammation in patients
with HCC after surgery through coenzyme Q10 to in-
crease the antioxidant capacity, particularly those with
a higher level of inflammation.
Regarding the safety of coenzyme Q10 supplementa-
tion in the present study, there were no clinically signifi-
cant changes in the subjects’ vital signs, serum chemical
values, or hematological values, and there were no ser-
ious adverse events, no complaints of myalgia or muscle
weakness, and no withdrawals due to adverse events.
Fig. 3 Correlations between changes in the levels of coenzyme Q10 and changes in the levels of oxidative stress, antioxidant enzymes activity,
and vitamin E. a Correlation between the changes in the levels of coenzyme Q10 and MDA (β = -0.29, p = 0.02); b Correlation between the
changes in the levels of coenzyme Q10 and SOD (β = 2.57, p = 0.02); c Correlation between the changes in the levels of coenzyme Q10 and CAT
(β = 4.47, p < 0.01); d Correlation between the changes in the levels of coenzyme Q10 and GPx (β = 3.53, p = 0.03); e Correlation between the
changes in the levels of coenzyme Q10 and vitamin E (β = 1.44, p = 0.01). CAT, catalase activity; GPT, glutamic oxaloacetic transaminase; GPx,
glutathione peroxidase; HCC, hepatocellular carcinoma; MDA, malondialdehyde; SOD, superoxide dismutase
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Note that the level of GPT was significantly decreased
after the coenzyme Q10 supplementation (data not
shown, 55.5 ± 39.8 IU/L decreased to 49.1 ± 46.2 IU/L, p
= 0.02) and that changes in the levels of coenzyme Q10
were significantly correlated with changes in the levels
of GPT (data not shown, β = -10.09, p = 0.03). In
addition to GPT, the level of high density lipoprotein-
cholesterol (HDL-C) was significantly increased after the
coenzyme Q10 supplementation (data not shown, 1.3 ±
0.3 mmol/L increased to 1.5 ± 0.4 mmol/L, p < 0.01).
Thus, at a dose of 300 mg/d coenzyme Q10 is safe for
patients with HCC, and it protects against cardiotoxicity
or liver toxicity during cancer treatment [32]. Our study
has two limitations should be mentioned. First, the num-
ber of participants was small, although we did recruit
more subjects than expected. Second, this study was de-
signed for 12 weeks intervention only. Larger and longer
intervention studies are needed to confirm the beneficial
effect of coenzyme Q10 supplementation in patients
with HCC after surgery.
Conclusion
In conclusion, this clinical study is the first to demonstrate
that a dose of 300 mg/d of coenzyme Q10 supplementa-
tion significantly increased antioxidant capacity and
reduced the levels of inflammatory markers (hs-CRP and
IL-6) in patients with HCC after surgery. We suggest that
coenzyme Q10 supplementation could be considered as a
complementary treatment strategy for patients with HCC
after surgery, particularly those under higher levels of oxi-
dative stress and inflammation.
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